FDA warned Talon Pharmacy of Boerne that it made sterile compounded drugs under insanitary conditions that could contaminate them.
What happened
FDA inspected Vita Pharmacy, LLC dba Talon Pharmacy of Boerne in Boerne, Texas, from October 18 to November 2, 2021, and issued a Form FDA 483 (a list of inspection findings) on the last day. The investigator found that sterile drug products were prepared under insanitary conditions: air could flow from lower-quality into higher-quality clean areas, hazardous and non-hazardous drugs were made in the same cleanroom, equipment was visibly dirty, materials were not disinfected when transferred into the ISO5 area, smoke (airflow) studies had never been done in the ISO5 biological safety cabinet, and media fills (test batches used to show sterile production works) were not run under worst-case conditions. FDA reviewed the firm's November 15, 2021 response and found most of the proposed fixes lacking in detail, timing, or recertification plans.
What FDA found
The facility's design and operation may let lower-quality air enter higher-quality clean areas, because a curtain and a wall separating the classified spaces were not properly sealed.
FDCA section 501(a)(2)(A) [21 U.S.C. ยง 351(a)(2)(A)]Hazardous drugs were made in a biological safety cabinet inside the same cleanroom as non-hazardous drugs, without adequate containment and segregation to prevent cross-contamination.
FDCA section 501(a)(2)(A)Equipment in the classified areas was visibly dirty with hard-to-clean surfaces, including an unknown foreign substance stuck to the plastic grille of a HEPA filter in the ISO5 area.
FDCA section 501(a)(2)(A)Staff did not disinfect materials when moving them from the ISO7 cleanroom into the ISO5 area.
FDCA section 501(a)(2)(A)The firm never performed smoke studies (airflow visualization) under dynamic conditions in the ISO5 biological safety cabinet, and the cabinet was not included in the January and July 2021 certification reports.
FDCA section 501(a)(2)(A)Media fills were not performed under the most challenging or stressful conditions, so there is no assurance the firm can make sterile drug products aseptically.
FDCA section 501(a)(2)(A)
What FDA wants
Within 15 working days, notify the office in writing on company letterhead of the specific steps taken to correct the violations, with an explanation of each step and supporting documents, referring to case number 639220. FDA also strongly recommends that management do a comprehensive assessment of the operation, including facility design and aseptic processing, with the help of a third-party consultant who has sterile drug manufacturing expertise.
Who should pay attention
- hospitals and clinics that buy compounded sterile drugs
- other compounding pharmacies making sterile or hazardous drugs
- health systems and prescribers that outsource sterile compounding
This is a summary. Read the original letter on fda.gov.